NYSE:NVTA - InVitae Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $8.41 -0.26 (-3.00 %) (As of 07/22/2018 08:34 AM ET)Previous Close$8.41Today's Range$8.27 - $8.7052-Week Range$4.35 - $10.41Volume408,124 shsAverage Volume670,375 shsMarket Capitalization$565.19 millionP/E RatioN/ADividend YieldN/ABeta1.2 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It also operates Patient Insights Networks, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform that is used for the collection, analysis, and management of patient family history information. Invitae Corporation serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California. Receive NVTA News and Ratings via Email Sign-up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Medical laboratories Sub-IndustryN/A SectorMedical SymbolNYSE:NVTA CUSIPN/A Webinvitae.com Phone415-374-7782 Debt Debt-to-Equity Ratio0.60 Current Ratio2.53 Quick Ratio2.53 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$68.22 million Price / Sales8.29 Cash FlowN/A Price / CashN/A Book Value$2.30 per share Price / Book3.66 Profitability EPS (Most Recent Fiscal Year)($2.65) Net Income$-123,380,000.00 Net Margins-154.96% Return on Equity-127.38% Return on Assets-68.70% Miscellaneous Employees594 Outstanding Shares67,210,000Market Cap$565.19 InVitae (NYSE:NVTA) Frequently Asked Questions What is InVitae's stock symbol? InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA." How were InVitae's earnings last quarter? InVitae Corp (NYSE:NVTA) issued its quarterly earnings data on Wednesday, May, 9th. The medical research company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.05. The medical research company had revenue of $27.67 million for the quarter, compared to analyst estimates of $26.86 million. InVitae had a negative return on equity of 127.38% and a negative net margin of 154.96%. The business's quarterly revenue was up 167.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.64) earnings per share. View InVitae's Earnings History. When is InVitae's next earnings date? InVitae is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for InVitae. What price target have analysts set for NVTA? 4 brokers have issued 1-year price targets for InVitae's stock. Their predictions range from $9.00 to $15.00. On average, they anticipate InVitae's stock price to reach $11.00 in the next year. This suggests a possible upside of 30.8% from the stock's current price. View Analyst Ratings for InVitae. What is the consensus analysts' recommendation for InVitae? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of InVitae's key competitors? Some companies that are related to InVitae include Genomic Health (GHDX), Natera (NTRA), RadNet (RDNT), CareDx (CDNA), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), Biocept (BIOC) and OpGen (OPGN). Who are InVitae's key executives? InVitae's management team includes the folowing people: Dr. Randal W. Scott, Exec. Chairman (Age 60)Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 44)Ms. Shelly D. Guyer, Chief Financial Officer (Age 58)Mr. Lee Bendekgey, Chief Operating Officer (Age 60)Ms. Patricia E. Dumond, Chief Accounting Officer & VP of Fin. (Age 53) When did InVitae IPO? (NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers. Has InVitae been receiving favorable news coverage? News coverage about NVTA stock has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. InVitae earned a daily sentiment score of 0.15 on Accern's scale. They also assigned media coverage about the medical research company an impact score of 45.89 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days. Who are InVitae's major shareholders? InVitae's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include ARK INVESTMENT MANAGEMENT LLC (10.84%), Daiwa SB Investments Ltd. (0.75%) and Bank of Montreal Can (0.03%). Company insiders that own InVitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Institutional Ownership Trends for InVitae. Which major investors are buying InVitae stock? NVTA stock was purchased by a variety of institutional investors in the last quarter, including Daiwa SB Investments Ltd. and Bank of Montreal Can. Company insiders that have bought InVitae stock in the last two years include Bros Advisors Lp Baker, Geoffrey Crouse and Randal W Scott. View Insider Buying and Selling for InVitae. How do I buy shares of InVitae? Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is InVitae's stock price today? One share of NVTA stock can currently be purchased for approximately $8.41. How big of a company is InVitae? InVitae has a market capitalization of $565.19 million and generates $68.22 million in revenue each year. The medical research company earns $-123,380,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. InVitae employs 594 workers across the globe. How can I contact InVitae? InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected] MarketBeat Community Rating for InVitae (NYSE NVTA)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 188 (Vote Outperform)Underperform Votes: 211 (Vote Underperform)Total Votes: 399MarketBeat's community ratings are surveys of what our community members think about InVitae and other stocks. Vote "Outperform" if you believe NVTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: What is the Book Value of a Share?